Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,675

Document Document Title
WO/2018/190643A1
The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazol...  
WO/2018/187623A1
The present invention provides crystalline forms of compound of formula (la) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and crystalline forms for treating or preventing ...  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/178008A1
Described are substituted isoxazoline-5-ones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing th...  
WO/2018/172480A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.  
WO/2018/172471A1
The present invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds; to intermediate...  
WO/2018/172306A1
The invention relates to a compound that inhibits interaction between a Grb14 protein and an insulin receptor, of formula (I) or of formula (II), the salts, solvates and/or diastereoisomers thereof, for use for therapeutic purposes, in p...  
WO/2018/172997A1
A compound of Formula (I)) or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 through R3, and L are as defined herein.  
WO/2018/165718A1
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and ...  
WO/2018/170173A1
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...  
WO/2018/167468A1
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...  
WO/2018/157842A1
The present invention provides a use of 2-(substituted phenylamino)benzoic acid FTO inhibitor in treating leukemia.  
WO/2018/157801A1
The present invention relates to a cyano group-substituted fused bicyclic derivative, and a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used for inhibiting xanthine oxidase an...  
WO/2018/151678A1
The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereo...  
WO/2018/144718A1
Prodrugs of glutamine analogs, such as prodrugs of acivicin, are disclosed.  
WO/2018/144101A1
Described herein are labeling agents, specifically [11C]fluoroform, [11C]difluoromethane, [11C]fluoromethyl iodide, [11C]fluoromethyl bromide, [11C]fluoromethyl chloride, [11C]fluoromethyl trifluoromethansulfonate, [11C]difluoromethyl io...  
WO/2018/140599A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 ...  
WO/2018/133716A1
The present invention provides a heterocyclic urea compound as an indoleamine-2,3-dioxygenase inhibitor, a preparation method thereof, and a use of the heterocyclic urea compound as an indoleamine-2,3-dioxygenase inhibitor or a pharmaceu...  
WO/2018/133730A1
Disclosed in the present invention are a farnesoid X receptor (FXR) agonist compound and a preparation method and use therefor. Specifically, provided in the present invention are a heterocyclic FXR agonist compound, as well as stereoiso...  
WO/2018/133870A1
A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.  
WO/2018/135649A1
Provided are: an isoxazolin-5-one derivative represented by general formula (1); and a herbicide which contains the isoxazolin-5-one derivative as an active ingredient. In general formula (1), R1 represents a C1-C6 haloalkyl group; R2-R4...  
WO/2018/107415A1
The present invention relates to a compound represented by formula (I) : and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disor...  
WO/2018/111734A1
The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disord...  
WO/2018/104307A1
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...  
WO/2018/106284A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2018/102574A1
An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric ...  
WO/2018/102574A8
An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric ...  
WO/2018/102574A9
An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric ...  
WO/2018/089402A1
There are described RORĪ³ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...  
WO/2018/081285A1
The present invention provides compounds of Formula (I), Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR- mediated or TGR5-med...  
WO/2018/075207A1
The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, inc...  
WO/2018/067704A1
The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.  
WO/2018/064119A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2018/055235A1
The present invention concerns compounds of Formula 1a and its uses as a drug, particularly in treatment of cardiac diseases, and in methods and products relating to cell differentiation.  
WO/2018/053587A1
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.  
WO/2018/050631A1
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...  
WO/2018/049328A1
Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.  
WO/2018/046337A1
The present invention discloses solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) selected from an amorphous form or a crystalline anhydrous form. The invention also discloses solid solvates of ingenol 3-(3,5-diethylisoxazole...  
WO/2018/049324A1
Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.  
WO/2018/045149A1
Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is -OH or -OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists ...  
WO/2018/029150A1
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...  
WO/2018/024188A1
Provided are a polycyclic compound and a manufacturing method, pharmaceutical composition, and application thereof. The structure of the polycyclic compound and an isomer, prodrug, solvate, hydrate, stable isotopic derivative, or pharmac...  
WO/2018/026997A1
The present invention relates to- chimeric (including Afunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer ...  
WO/2018/024224A1
A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the ...  
WO/2018/026997A9
The present invention relates to- chimeric (including Afunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer ...  
WO/2018/018091A1
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.  
WO/2018/014858A1
Provided are a crystal and salt of an m-dihydroxybenzene represented by (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-induced disease.  
WO/2018/001084A1
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a heat shock protein inhibitor, and a manufacturing method and application thereof. The heat shock protein inhibitor has a characteristic structure rep...  
WO/2017/219083A1
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...  
WO/2017/223188A1
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.  

Matches 1 - 50 out of 6,675